MX2019012506A - Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. - Google Patents

Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.

Info

Publication number
MX2019012506A
MX2019012506A MX2019012506A MX2019012506A MX2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A
Authority
MX
Mexico
Prior art keywords
myostatin
bind
domain proteins
stable formulations
based scaffold
Prior art date
Application number
MX2019012506A
Other languages
English (en)
Inventor
C Nashine Vishal
K Patel Rushikesh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019012506A publication Critical patent/MX2019012506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

La presente invención se refiere en general a formulaciones líquidas estables que comprenden polipéptidos con los dominios 10Fn3 los cuales se unen a la miostatina y a las formas de dosificación unitaria de las mismas para varias rutas de administración, incluida la subcutánea (SC), para tratar emaciación de masa muscular y trastornos metabólicos.
MX2019012506A 2017-05-03 2018-05-03 Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. MX2019012506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500649P 2017-05-03 2017-05-03
PCT/US2018/030851 WO2018204617A1 (en) 2017-05-03 2018-05-03 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin

Publications (1)

Publication Number Publication Date
MX2019012506A true MX2019012506A (es) 2019-12-19

Family

ID=62223280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012506A MX2019012506A (es) 2017-05-03 2018-05-03 Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.

Country Status (12)

Country Link
US (1) US20200129595A1 (es)
EP (1) EP3618809A1 (es)
JP (2) JP7157082B2 (es)
KR (1) KR20200003076A (es)
CN (1) CN110621302A (es)
AU (1) AU2018261154B2 (es)
CA (1) CA3062797A1 (es)
IL (2) IL305625A (es)
MX (1) MX2019012506A (es)
SG (1) SG11201909709SA (es)
TW (1) TW201842929A (es)
WO (1) WO2018204617A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
ES2564161T3 (es) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1968621A2 (en) 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
US20100322930A1 (en) 2007-12-27 2010-12-23 Frank Kolbinger Fibronectin-based binding molecules and their use
WO2009102421A2 (en) * 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
BR112012019881A2 (pt) * 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9562089B2 (en) * 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
CA2879139C (en) * 2012-07-18 2021-05-11 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
HUE050894T2 (hu) * 2015-04-17 2021-01-28 Bristol Myers Squibb Co Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Also Published As

Publication number Publication date
IL270233B2 (en) 2024-02-01
AU2018261154A1 (en) 2019-11-07
AU2018261154B2 (en) 2024-05-02
JP7442595B2 (ja) 2024-03-04
WO2018204617A8 (en) 2019-01-03
EP3618809A1 (en) 2020-03-11
JP2020518603A (ja) 2020-06-25
IL270233B1 (en) 2023-10-01
WO2018204617A1 (en) 2018-11-08
CN110621302A (zh) 2019-12-27
JP7157082B2 (ja) 2022-10-19
JP2023011601A (ja) 2023-01-24
IL305625A (en) 2023-11-01
US20200129595A1 (en) 2020-04-30
IL270233A (es) 2019-12-31
KR20200003076A (ko) 2020-01-08
TW201842929A (zh) 2018-12-16
SG11201909709SA (en) 2019-11-28
CA3062797A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
AU2021200367B2 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
MX2016003182A (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201592214A1 (ru) Модулятор рецептора эстрогена и его применения
BR112016020368A2 (pt) proteínas fc multiméricas
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201591839A1 (ru) Терапевтические пептиды
MX2016016337A (es) Polipeptidos apelina.
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use